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Abstract
Background: Diarrheal infections caused by Salmonella, are one of the major causes of childhood morbidity and
mortality in developing countries. Salmonella causes various diseases that range from mild gastroenteritis to enteric
fever, depending on the serovar involved, infective dose, species, age and immune status of the host. Probiotics
are proposed as an attractive alternative possibility in the prevention against this pathogen infection. Previously we
demonstrated that continuous Lactobacillus casei CRL 431 administration to BALB/c mice before and after
challenge with Salmonella enterica serovar Typhimurium (S. Typhimurium) decreased the severity of Salmonella
infection. The aim of the present work was to deep into the knowledge about how this probiotic bacterium exerts
its effect, by assessing its impact on the expression and secretion of pro-inflammatory (TNFa, IFNg) and anti-
inflammatory (IL-10) cytokines in the inductor and effector sites of the gut immune response, and analyzing toll-
like receptor (TLR2, TLR4, TLR5 and TLR9) expressions in both healthy and infected mice.
Results: Probiotic administration to healthy mice increased the expression of TLR2, TLR4 and TLR9 and improved
the production and secretion of TNFa, IFNg and IL-10 in the inductor sites of the gut immune response (Peyer’s
patches). Post infection, the continuous probiotic administration, before and after Salmonella challenge, protected
the host by modulating the inflammatory response, mainly in the immune effector site of the gut, decreasing
TNFa and increasing IFNg, IL-6 and IL-10 production in the lamina propria of the small intestine.
Conclusions: The oral administration of L. casei CRL 431 induces variations in the cytokine profile and in the TLRs
expression previous and also after the challenge with S. Typhimurium. These changes show some of the immune
mechanisms implicated in the protective effect of this probiotic strain against S. Typhimurium, providing an
alternative way to reduce the severity of the infection.
Background
Diarrheal infections caused by bacterial enteric patho-
gens including Salmonella, are one of the major causes
of childhood morbidity and mortality in developing
countries [1]. Salmonella enterica serovar Typhimurium
(S. Typhimurium) is an intracellular Gram-negative bac-
terium characterized by its ability to survive and
replicate within eukaryotic host cells, particularly epithe-
lial cells and macrophages. In humans, while Salmonella
enterica serovar Typhi typically causes severe or some-
times lethal systemic illness called “Typhoid Fever”, Sal-
monella Typhimurium is associated with self limiting
gastroenteritis and requires treatment only in immuno-
compromised patients. S. Typhimurium develops in
mice an infection with the same pathogenesis and clini-
cal manifestations than S. Typhi in humans thus, this
mouse model is useful for the study of this disease [2].
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The intestine harbours trillions of commensal bacteria
that participate in digestive functions and help to pro-
tect the host from the aggression of several enteropatho-
gens [3]. The beneficial effects of the microbiota on the
host immune system have allowed the proposal to use
some non pathogenic bacteria, such as probiotics in
improving animal health and protection against infec-
tious agents [4]. Probiotics have been shown to influ-
ence both innate and adaptive immunity through direct
contact with epithelial and immune cells, or by their
ability to modify the composition and activity of the gut
microbiota. They exert their protective effects by multi-
ple immune and non immune mechanisms [5], i.e.,
exerting direct antimicrobial activity against pathogens
[6], increasing phagocytosis [7], modifying cytokine pro-
duction by different cell populations [8-10] or enhancing
IgA production [11]. One of the principal mechanisms
of protection against gastroenteric infections by probio-
tics is via modulation of pro-inflammatory (like IFNg
and TNFa) and anti-inflammatory (IL-10) cytokines, but
the pathways and cells involved in this mechanisms are
not clear yet [12]. It is a fact that not all microorganisms
have the same effect on the host, and that probiotic
properties are strain and host specific. In this sense, it is
not possible to extrapolate the effects found with one
probiotic strain to another, or its effect against a specific
pathogen to other pathogen [13].
L. casei CRL 431 is a probiotic bacterium and its
effects on the gut immune cells have been extensively
studied. In a previous work, the effect of L. casei CRL
431 in the prevention of S. Typhimurium infection in
BALB/c mice was evaluated. It was demonstrated that 7
days of L. casei CRL 431 administration before S. Typhi-
murium infection decreased its severity. The continuous
probiotic administration (before and after infection)
diminished the pathogen counts in the intestine as well
as its spread outside this organ. The probiotic adminis-
tration decreased the neutrophil infiltration with the
consequent diminution of intestinal inflammation; acti-
vated the macrophage phagocytic capacity in Peyer’s
patches, spleen and peritoneum; and increased the num-
ber of IgA(+) cells in the lamina propria of the small
intestine which was correlated with increased release of
s-IgA specific against the pathogen in the intestinal
fluids [7].
The aim of the present work was to deep into the
knowledge about how the probiotic bacterium L. casei
CRL 431 exerts its protective effect against S. Typhimur-
ium infection, by assessing the impact of this probiotic
strain on the cytokine profile (expression and secretion)
and in the expression of different Toll-like receptors
(TLRs) in the inductor and effector sites of the immune
response in the small intestine, in both healthy and
infected animals.
Results
Effect of L. casei CRL 431 administration on the cytokine
producing cells isolated from Peyer’s patches in animals
non infected or infected with Salmonella
Healthy mice that received the probiotic during 7 days (Lc
group) and mice non-treated with L. casei CRL431, but
challenged with Salmonella (infection control, S group) sti-
mulated the production of TNFa and IFNg by the immune
cells of the Peyer’s patches, compared to non-treated and
non-infected mice (untreated control, C) (Table 1). These
cytokine producing cells increased significantly (p < 0.01)
7days post challenge in the mice fed continuously (before
and after infection) with the probiotic strain (Lc-S-Lc
group), compared to the infection control (S group). No
significant differences with the infection control (S group)
were observed in the number of TNFa (+) cells isolated
from mice that stopped probiotic administration after infec-
tion (Lc-S group), while these last group showed signifi-
cantly (p < 0.01) decreased number of IFNg (+) cells
compared to the other two infected groups (Lc-S-Lc and S).
The analysis of IL-10 producer cells showed that 7 days of
probiotic administration (Lc group) and also Salmonella
challenge (S group) increased significantly (p < 0.01) the
number of these cells compared to the untreated control
(C group). Seven days after infection, both groups adminis-
tered L. casei CRL 431 decreased the number of IL-10 (+)
cells to values similar to C group (Table 1).
Measurement of cytokines released by immune cells
isolated from Peyer’s patches of mice untreated or
treated with the probiotic strain previous and post
infection
Cells isolated from Peyer’s patches of healthy mice fed 7
days with L. casei CRL 431 (Lc group) increased
Table 1 Cytokine producing cells isolated from Peyer’s
patches of mice untreated or treated with L. casei CRL
431 previous and post challenge with S. Typhimurium
Experimental groups N° of cytokine secreting cells
TNFa IFNg IL-10
C 10 ± 4a 13 ± 3ad 12 ± 3a
Lc 24 ± 9b 20 ± 3b 17 ± 1b
S 26 ± 4b 16 ± 1ab 22 ± 6b
Lc-S 36 ± 12b 12 ± 2d 9 ± 4a
Lc-S-Lc 75 ± 4c 41 ± 10c 13 ± 5a,b
Cytokine producing cells were analyzed by immunocytochemistry in
mononuclear cells isolated from Peyer’s patches of mice at 2 time points: the
day of the infection (basal data) for the untreated control (C) and for mice
given L. casei CRL 431 during 7 days (Lc), and 7 days post infection for
infection control (S), mice given probiotic 7 days before the infection (Lc-S),
and mice given continuously probiotic, before and after infection (Lc-S-Lc).
Results for healthy mice obtained the same day of the infected animals were
not added because there were not significant differences compared to the
basal data. Results are expressed as the means ± SD of the total number of
positive cells per 2 × 104 counted cells at 1 000X magnification. Means for
each value without a common letter differ significantly (P < 0.01).
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significantly (p < 0.01) the release of IFNg and IL-10
compared to the untreated control (C group). Seven
days after infection, the cells from the infection control
group (S) increased significantly (p < 0.01) the release of
IFNg and TNFa, compared to the untreated control (C).
However, at this time point, the IFNg levels in the cul-
ture supernatant of cells isolated from the two groups
fed with the probiotic strain (Lc-S and Lc-S-Lc groups)
decreased significantly (p < 0.01) compared to the infec-
tion control (S). The concentration of this cytokine from
Lc-S-Lc group was similar to those obtained from
healthy mice fed with L. casei (Lc group). The produc-
tion of TNFa did not show significant differences (p <
0.01) in all the groups after Salmonella infection. Seven
days after infection, the cells isolated from S and Lc-S
groups showed similar releases of IL-10, without signifi-
cant differences compared to healthy mice (C and Lc
groups). Continuous probiotic administration before and
after infection decreased significantly (p < 0.01) the IL-
10 release by the Peyer’s patches mononuclear cells
compared to the other infected groups, and the values
were similar to those obtained from cells of the
untreated control (C) (Table 2).
Effect of L. casei CRL 431 consumption on the cytokine
producing cells in the lamina propria of the small
intestine in healthy and infected mice
The results obtained in the basal samples, before S.
Typhimurium challenge, showed that the number of
IFNg (+) cells increased significantly (p < 0.01) in the
mice given probiotic during 7 days compared with the
untreated control (32 ± 10 cells/10 fields vs. 15 ± 6
cells/10 fields Figure 1B). At this time point, TNFa, IL-
6 and IL-10 positive cells remained similar in both
experimental groups (Figure 1A, C and 1D). TNFa (+)
cells were significantly (p < 0.01) increased in the infec-
tion control group (S) (54 ± 10 cells/10 fields) 7 days
post infection, compared with the basal data (31 ± 12
cells/10 fields and 31 ± 11 cells/10 fields for C and Lc
groups, respectively). Ten days post S. Typhimurium
infection, the number of cells positive for this cytokine
decreased in all the groups challenged, and the
decreases in the treated groups were significant (p <
0.01) compared to the basal samples (11 ± 4 cells/10
fields and 9 ± 2 cells/10 fields, for Lc-S and Lc-S-Lc,
respectively, Figure 1A). Seven days post challenge, the
continuous probiotic administration (Lc-S-Lc group)
maintained the number of IFNg (+) cells (21 ± 5 cells/
10 fields) similar to the basal data, being this number
significantly higher (p < 0.01) than the observed in the S
group at the same time point (11 ± 4 cells/10 fields).
Ten days post challenge the number of IFNg (+) cells
significantly decreased (p < 0.01) in the Lc-S-Lc group,
and no significant changes for this cytokine were
observed between the three infected groups and the
untreated control (C) (Figure 1B). The number of IL-6
(+) cells was significantly increased (p < 0.01) in the
three groups challenged with the pathogen 7 days post
infection, compared to the untreated control group (C).
At this time point, the Lc-S-Lc group also showed a sig-
nificant increase (p < 0.01) of IL-6 (+) cells compared to
all the groups. At day 10 post-challenge, the Lc-S-Lc
group maintained a number of IL-6+ cells higher than
both control groups (C and S, Figure 1C). Seven days
post challenge, the two groups fed with the probiotic
(Lc-S and Lc-S-Lc) showed significant (p < 0.01)
increases of IL-10 (+) cells compared to S group. No
significant differences were observed 10 days post infec-
tion in the different experimental groups (Figure 1D).
Cytokine profile on the small intestinal fluid
In the basal sample, after 7 days of feeding, the group Lc
showed similar levels of TNFa, IFNg, IL-6 and IL-10
released to the intestinal lumen than the untreated con-
trol (Figure 2A, B, C and 2D). The groups Lc-S and Lc-
S-Lc maintained TNFa concentration in the intestinal
fluid similar to basal groups in both samples, 7 and 10
days post challenge; while the release of TNFa was sig-
nificantly increased (p < 0.01) in mice from S group
compared to basal samples, 10 days post challenge (Fig-
ure 2A). IFNg levels were significantly higher (p < 0.01)
in mice administered continuously with the probiotic
(Lc-S-Lc) compared to the infection control group (S)
for 7 and 10 days post challenge (Figure 2B). The Lc-S
and Lc-S-Lc groups maintained IL-6 levels in the intest-
inal fluid similar to Lc group, 7 and 10 days post chal-
lenge. Nevertheless IL-6 release in S group was
Table 2 Effect of L. casei CRL 431 administration on the
cytokines released in cultures of immune cells isolated
from Peyer’s patches of mice untreated, treated and
infected with S. Typhimurium
Experimental groups Cytokine concentration (pg/ml)
TNFa IFNg IL-10
C 203 ± 32a 139 ± 83a 65 ± 13ac
Lc 257 ± 55ac 1175 ± 563bc 187 ± 91b
S 336 ± 90bcd 1384 ± 74c 102 ± 42ab
Lc-S 328 ± 4b 148 ± 86a 102 ± 24ab
Lc-S-Lc 432 ± 20d 592 ± 40b 34 ± 18c
The concentration of different cytokines were evaluated in supernatant of
cultures of cells isolated from Peyer’s patches of mice at 2 time points: the
day of the infection (basal data) for the untreated control (C) and for mice
given L. casei CRL 431 during 7 days (Lc), and 7 days post infection for
infection control (S), mice given probiotic 7 days before the infection (Lc-S)
and mice given continuously probiotic, before and after infection (Lc-S-Lc).
Cytokine concentration in the cell culture supernatants after 24 h of
incubation was determined by ELISA. Results are expressed as the means ±
SD of the concentrations of each cytokine released into the supernatant (pg/
ml). Means for each cytokine without a common letter differ significantly (P <
0.01).
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Figure 1 Determination of cytokine (+) cells in the small intestine tissues. Positive cells were counted in histological sections from small
intestine of mice fed 7 d with L. casei CRL 431 previous challenge with S. Typhimurium (Lc-S), and mice fed continuously (before and after
infection) with the probiotic bacteria (Lc-S-Lc), compared to the infection control (S). Tissues from healthy mice fed or not with L. casei (Lc and C
groups, respectively) were also analyzed. The samples were obtained the day of the infection (basal data) for Lc and C groups, and 7 and 10
days post challenge for all the groups. Representative microphotographs show the differences observed between C group (E and F), S group (G
and H), and Lc-S-Lc group (I and J) in the number of IL-6 (+) cells (arrows), 7 days post challenge. The microphotographs E, G and I were
obtained at 400× while F, H and J were taken at 1 000X. A difference of 1 cell at 1000× is related with 10 cells of difference in the final result.
Means for each value without a common letter differ significantly (P < 0.01).
Castillo et al. BMC Microbiology 2011, 11:177
http://www.biomedcentral.com/1471-2180/11/177
Page 4 of 12
significantly increased (p < 0.01) 7 days post challenge
compared to the untreated control (C), and this levels
remained high 10 days post challenge (Figure 2C). IL-10
concentration was significantly increased (p < 0.01) in
Lc-S and Lc-S-Lc groups compared to S group, for 7 and
10 days post-infection (Figure 2D).
Effect of probiotic administration and S. Typhimurium
infection on TLR2, TLR4, TLR5 and TLR9 expression in the
lamina propria of the small intestine
L. casei CRL 431 administration to healthy mice (Lc)
increased the expression of all the TLRs analyzed com-
pared to the untreated control (C) (Figure 3). Seven
days post infection, the mice that received continuously
L. casei CRL 431 (Lc-S-Lc group) showed a significant
(p < 0.01) increase of TLR2 (+) and TLR5 (+) cells (30
± 10 cells/10 fields and 18 ± 2 cells/10 fields, for TLR2
and TLR5 respectively) compared to S group (14 ± 5
cells/10 fields and 9 ± 2 cells/10 fields, respectively)
(Figure 3A and 3C). At this time point, TLR9 (+) cells
increased significantly (p < 0.01) in both treated groups
(Lc-S and Lc-S-Lc), compared to the untreated control
(C) (Figure 3D). TLR4 (+) cells increased significantly (p
< 0.01) in the infection control group (S) and in mice
fed continuously with the probiotic strain (Lc-S-Lc)
compared to the untreated control (C), (Figure 3B). For
10 days post challenge, TLR2, TLR4 and TLR9 (+) cells
of mice from infected groups (S, Lc-S and Lc-S-Lc)
showed values similar to the untreated control (C), (Fig-
ure 3A, B and 3D). For TLR5 the mice from the group
Lc-S-Lc maintained significantly increased (p < 0.01) the
expression of this receptor in comparison with the
untreated control (C), (Figure 3C).
Discussion
A previous work demonstrated that L. casei CRL 431
administration induced activation of the immune cells
associated to the small intestine of mice that received
the probiotic strain [4]. We also observed that this pro-
biotic strain decreased the severity of S. Typhimurium
Figure 2 Determination of the concentration of TNFa, IFNg IL-10 and IL-6 in intestinal fluid by ELISA. The samples were taken before the
infection for the untreated (C) and L. casei CRL 431(Lc) groups, and 7 and 10 days post challenge for all the experimental groups. The results
were expressed as the means ± SD of the concentration of each cytokine in pg/ml. Means for each value without a common letter differ
significantly (P < 0.01).
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Figure 3 Determination of TLRs (+) cells in histological sections of small intestine. The samples were obtained before the infection for the
untreated control (C) and healthy mice given L. casei CRL431 (Lc group), and 7 and 10 days post challenge for all experimental groups. The
number of fluorescent cells was counted in 30 fields of vision at 1 000X of magnification and the results were expressed as the number of
positive cells counted per 10 fields. The microphotographs (400×) F and H show the increases of TLR2+ and TLR4+ cells, respectively (fluorescent
cells) in mice from Lc group compared to the untreated control (C group: E for TLR2 and G for TLR4). Means for each value without a common
letter differ significantly (P < 0.01).
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infection in a mouse model, showing the continuous
administration, the best effect. Continous probiotic
administration decreased the mortality percentage (ten
times) and the CFU/g of Salmonella in liver, spleen and
large intestine for 7 and 10 days post- infection [7]. In
the present work, some immune mechanisms by which
L. casei CRL 431 administration exerts its protective
effect against Salmonella infection were analyzed, as the
intestinal cytokine profile in the inductor (Peyer’s
patches) and effector sites (lamina propria) of the gut
immune response. The modulation of TLRs expressions
was also determined in the small intestine tissues.
Previous to the infection, analyzing the mononuclear
cells isolated from Peyer’s patches, it was observed that
mice fed 7 days with L. casei CRL 431 significantly
increased cytokines expression and also the release of
IFNg and IL-10 by these cells. The production of cyto-
kines in Peyer’s patches was maintained without signifi-
cant differences in healthy animals that received the
probiotic strain (Lc) during all the experiment. These
cytokines were also studied 7 days post infection and it
was observed that mice from infection control group (S)
and the group fed continuously with the probiotic strain
maintained increased expression of both TNFa and
IFNg in the cells isolated from Peyer’s patches. Never-
theless, the release of IFNg from these cell cultures was
significantly higher in the infection control (S) than in
the mice given probiotic (Lc-S-Lc group). The increases
of these cytokines in Peyer’s patches are important
because they constitute the main inductor site for
mucosal immune response. In S. Typhimurium infec-
tion, this site is one of the pathways that Salmonella
uses to invade the host, although Salmonella infection
can also occur through the intestinal epithelial cells
along the small intestine [14]. Therefore post infection,
we also focused on the cytokine expression in cells from
the lamina propria of the small intestine and the cyto-
kines secretion into the intestinal lumen, due to this is
the effector site of the gut immune response (Figure 1
and 2). TNFa is a pro-inflammatory cytokine that
induces activation and recruitment of neutrophils
involved in local inflammatory processes, and produces
intestinal epithelial barrier dysfunction, contributing to
the entry and colonization of pathogenic bacteria usually
excluded from the subepithelial mucosa [15-17]. Seven
days post infection, the probiotic administration (Lc-S
and Lc-S-Lc grups) was able to maintain TNFa produc-
tion in the lamina propria of the small intestine and its
secretion to the intestinal fluid similar to the observed
in the non infected groups (C and Lc groups). These
values showed a tendency to decrease 10 days post chal-
lenge. In contrast, the infection control group signifi-
cantly increased TNFa expression 7 days post challenge
as well as its secretion 10 days post infection (Figure 2).
The TNFa modulation by probiotic administration
could be related with the lesser polymorphonuclear infil-
tration and inflammation degree in the lamina propria
observed previously [7]. Otherwise, the positive cells for
this cytokine and its release from these cells were
increased in Peyer’s patches when the mice received
continuously the probiotic strain compared to the
untreated control (C). These increments could be
related with the high number of activated macrophages
present in these sites, suggesting that TNFa is required
in the inductor site to maintain the immune response
against Salmonella (Tables 1 and 2). IFNg is implicated
in the immune activation by probiotic bacteria and fer-
mented milks. It contributes in the activation of macro-
phages to promote the effective killing of pathogens that
can survive within them. In our model, the number of
IFNg (+) cells in small intestinal tissues was significantly
lower in the group of mice from the infection control
group (S) than in the group of mice given continuously
L. casei CRL 431, which maintained the number of
these positive cells similar to the Lc group (Figure 1B).
As regard to the release of IFNg to the intestinal fluid,
the administration of the probiotic bacteria maintained
the levels of this cytokine similar to the basal data, at
difference of the S group, which showed a significant
decrease of IFNg concentration after infection (Figure
2B). IFNg (+) cells also increased in healthy mice given
probiotic bacteria in both inductor and effector sites of
the immune response compared to the untreated con-
trol group (Figure 1B and Table 1). This is consistent
with previous reports where the administration of pro-
biotic suspensions or fermented milks was associated
with increased number of IFNg (+) cells in the small
intestine of mice [4,18]. Recent findings revealed an
inhibitory effect of IFNg on neutrophils trafficking and
pro-inflammatory Th17 cells differentiation [19-21].
According to this observation, the increased levels of
this cytokine in Lc-S-Lc group could be correlated with
the reduced spread of Salmonella and the lower inflam-
mation of small intestinal tissues observed previously
[7]. IL-6 was analyzed because promotes both B cell
maturation [22] and pro-inflammatory activity [23]. It
was observed that 7 days after Salmonella challenge, the
production of this cytokine in the small intestine tissues
was significantly increased in the three infected groups
compared with the untreated control (C), and 10 days
post-challenge, only the group Lc-S-Lc maintained a
number of IL-6 (+) cells higher than both control
groups (C and S, Figure 1C). However, in the mice fed
continuously with the probiotic (Lc-S-Lc group), the IL-
6 release into the intestinal lumen remained stable 7
and 10 days post-infection. In contrast, the infection
control group (S) significantly increased IL-6 secretion
during all the experiment, compared with basal data
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(Figure 2C). These results showed that probiotic admin-
istration can down regulate the release of IL-6 but
maintain increased production of this cytokine in the
intestine which could be used by the host if it is
required.
According with the results obtained for the mentioned
cytokines, IL-10 was studied as an anti-inflammatory
cytokine and similar to IL-6 is required to maintain the
IgA (+) B cell population [24,25]. In our work, 7 days
post challenge the number of IL-10 (+) cells was signifi-
cantly higher in infected mice that received probiotic
administration than in mice from S group, (Figure 1D).
As regard to this cytokine release, the concentration of
IL-10 in the intestinal fluid was significantly decreased
in the infected control group (S) throughout the study,
while in mice from Lc-S group the significant decrease
was observed 10 days post infection. At day 7 post-chal-
lenge, IL-10 release of Lc-S-Lc group was lower than
absolute control (group C) and Lc group, but restored at
day 10 post-challenge. These results highlight the
importance of continuous probiotic administration in
the modulation of the immune response (Figure 2D).
Previous results obtained in our group suggested that
probiotic administration modulates the cytokine profile,
mainly in the cells from the innate immune response
through TLRs stimulation [4,26]. According to this, and
considering the differences observed for the cytokines,
we analyzed the expression of TLRs in immune and
epithelial cells of the small intestine in our infection
model.
TLR2 was studied due this receptor recognize the pep-
tidoglycan which is the principal component of the
Gram+ bacteria such as Lactobacillus genus. Our results
showed a significant increase of TLR2 (+) cells in the
small intestine of healthy mice that received L. casei
CRL 431 compared to the untreated control (Figure 3A)
and significant increases were also observed, only for 7
days post infection, in the mice given continuously the
probiotic bacteria (Lc-S-Lc group) compared to the
infection control (S group). This result agrees with other
findings describing a similar effect induced by two Lac-
tobacillus strains, L. rhamnosus GG and L. plantarum
BFE 1685, which enhanced TLR2 in vitro using human
intestinal cells [10]. We consider that the probiotic
strain stimulates the TLR2 not only to increase the sig-
nals to produce cytokines, but also to increase the
epithelial barrier because it was demonstrated TLR2
activation have an important role in enhancing trans-
epithelial resistance to invading bacteria [27]. Another
receptor analyzed was TLR4, which recognizes the LPS
present in the cell wall of the Gram(-) bacteria [28]. It is
known that TLR4 plays a significant role in the host
defences against Salmonella infection in vivo [29-31]. In
our model, L. casei CRL 431 administration to healthy
mice increased the number of TLR4 (+) cells compared
to the untreated control, which could be used as a sur-
veillance mechanism against pathogen bacteria such as
Salmonella. Recent findings suggest that the activation
of this receptor initiates an innate immune response
leading to the induction of pro-inflammatory mediators,
to increase TLR2 expression, and to reduce its own
expression, which leads to the recruitment of inflamma-
tory cells and the initiation of the appropriate responses
in the spleen leading control of the bacterial multiplica-
tion [29,32]. This is consistent with the results obtained
in our study where the enhancement of TLR4 was
accompanied of increased number of TLR2 (+) cells pre-
vious and post infection (Figure 3). The early increase in
the expression of TLR4 could be related with the
decrease of the severity of the infection observed in the
treated groups where the bacterial growth in the spleen
and the liver decreased faster than in the infection con-
trol [7].
TLR5 was evaluated because flagellated bacteria,
including E. coli and Salmonella, can interact with TLR5
to induce activation of pro-inflammatory gene programs
for host protection [33-35]. In the present work, we
observed that probiotic administration increased TLR5
(+) cells after Salmonella infection in both groups that
received the probiotic strain for 7 days post challenge
compared to untreated mice (C, Figure 3C). This finding
agrees with other study where two lactobacilli were able
to increase the cell surface expression of TLR5 in HT29
cells to respond to S. Typhimurium [10]. In our model,
this receptor could be also implicated in the protective
effect of L. casei CRL 431 against S. Typhimurium
infection.
Finally, in our study, it was observed that L. casei CRL
431 oral administration increased TLR9 expression in
healthy mice (Figure 3D). Seven days post infection, the
increase of TLR9 (+) cells was observed in both groups
of mice given probiotic bacteria (Lc-S and Lc-S-Lc), but
not in the infection control (S group), comparing with
the untreated control group (C). This finding agrees
with several works which affirm that CpG-TLR9 interac-
tion can improve the resistance of normal adult mice to
a variety of bacterial, viral and parasitic pathogens
[36-38], including increased resistance to oral challenge
with S. Typhimurium. TLR9 signalling is also required
to mediate an anti-inflammatory effect induced by pro-
biotics, in a mouse colitis model [39].
Conclusions
The results of the present work demonstrated the
importance of L. casei CRL 431 continuous administra-
tion, before and after S. Typhimurium infection, to
maintain the mechanisms of protection against this
pathogen. L. casei CRL 431 administration before
Castillo et al. BMC Microbiology 2011, 11:177
http://www.biomedcentral.com/1471-2180/11/177
Page 8 of 12
infection maintained the innate immune system in alert
state, through modulated expression of TLRs and cyto-
kine signals in the effector and inductor site of the gut
immune system, which could be related with the protec-
tion against S. Typhimurium observed in a previous
report. The results from the present work show that
once established the disease, the continuous L. casei
CRL 431 administration protected the host mainly mod-
ulating the inflammatory response against the entero-
pathogen in both effector and inductor sites of the gut.
This preliminary study shows some of the immune
mechanisms implicated in the protective effect of L.
casei CRL 431 againts S. Typhimurium infection. More
studies should be performed to validate the use of this
probiotic strain in the prevention and as a complement
to treatments in the defense against salmonellosis.
The cellular populations involved in the cytokine pro-
duction and how TLRs activate the different signals and
the transcriptional factors for cytokine production are
currently under study.
Methods
Animals and experimental groups
Five-week-old BALB/c mice weighting 22-26 g were
obtained from the closed random bred colony main-
tained at CERELA (Centro de Referencia para Lactoba-
cilos, San Miguel de Tucumán, Argentina). The assays
were performed using 3 experimental groups to assess
the effect of the preventive or continuous probiotic
administration against S. Typhimurium infection com-
paring with the infection control group (S). The same
number of female and male mice was distributed in all
the groups.
For the study of the mechanisms involved in the pre-
ventive effect, mice received L. casei CRL 431 for 7 con-
secutive days before challenge with the enteropathogen
(Lc-S group). For the effect of the continuous probiotic
administration, mice were administered L. casei CRL
431 during 7 days, challenged with the pathogen and
then continued receiving L. casei CRL 431 post chal-
lenge (Lc-S-Lc group). Mice of the infection control
group (S) did not receive special feeding and were chal-
lenged with S. Typhimurium. Additionally, two control
groups without infection (healthy mice) were analyzed: a
group of mice received L. casei CRL 431 (Lc group), and
the other group did not received special feeding
(untreated control group, C). Mice were euthanized and
the samples were collected after 7 days (the day of the
infection) for Lc and C groups, and 7 and/or 10 days
post challenge (depending on the assay performed) for
all the groups.
All animal protocols were pre-approved by the Animal
Protection Committee of CERELA and all experiments
complied with the current laws of Argentina.
Bacterial strains
L. casei CRL 431 was obtained from the CERELA cul-
ture collection. Overnight cultures were grown at 37°C
in sterile Mann-Rogosa-Sharp (MRS) broth (Britania,
Buenos Aires, Argentina). The cells were harvested by
centrifugation at 5 000g for 10 minutes, washed three
times with fresh PBS and then resuspended in sterile
10% (vol/vol) non-fat milk. L. casei CRL 431 was admi-
nistered to the mice in the drinking water to reach a
concentration of 1 × 108 CFU/ml. This lactobacilli
count was periodically controlled at the beginning and
after 24 h of dilution in water (maintained in the same
room where the mice are) to avoid modifications of
more than 1 logarithmic unit.
S. Typhimurium strain was obtained from the Bacter-
iology Department of the Hospital del Niño Jesús (San
Miguel de Tucumán, Argentina). An aliquot (200 μl)
from an overnight culture was placed in 5 ml of sterile
Brain Heart Infusion (BHI) broth (Britania, Buenos Aires,
Argentina) and incubated during 4 hours. The concentra-
tion of Salmonella was adjusted to 1 × 108 CFU/ml in
phosphate buffered saline (PBS). Each mouse was chal-
lenged with 100 μl of 1 × 108 CFU/ml of S. Typhimurium
given by gavage. This dose was selected in our previous
work because induce 50% of mice mortality [7].
Isolation and culture of immune cells from Peyer’s
patches for cytokine determination
The protocol described by Galdeano and Perdigón [11]
was used for the isolation of cells from Peyer’s patches.
The cells were isolated after 7 days of feeding for Lc
and C groups and 7 days post Salmonella infection for
all the challenged groups. The small intestine of each
mouse was removed, washed and the Peyer’s patches
were excised in Hank’s buffered salt solution (HBSS)
containing 4% foetal bovine serum (FBS). The epithe-
lium cells were separated with HBSS/FBS solution con-
taining EDTA. The sediments were incubated with
dispase/DNAse solution and the mononuclear cells were
recovered. The cells were collected and washed with
RPMI 1640 medium (Sigma, St. Louis, USA). The cells
concentrations were adjusted in RPMI and cultured in a
CO2 incubator. The culture supernatants were recovered
after 4 h and 24 h for TNFa and after 24 h to analyze
the levels of IFNg and IL-10 using ELISA technique. BD
OptEIA mouse cytokine ELISA sets from BD Bioscience
(San Diego, USA) were used according manufacturer
instructions. The results were expressed as concentra-
tion of each cytokine (pg/ml).
Detection of cytokine producing cells isolated from
Peyer’s patches
Mononuclear cells were isolated from Peyer’s patches as
described above. 20 μl of each cell suspension (1 × 106)
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was placed per well in special glass slides by triplicate.
They were fixed 15 minutes with BD Pharmigen ICC
Fixation Buffer. TNFa, IFNg and IL-10 were determined
by immunocytochemistry following the technique
described by Dogi et al [40]. Briefly, the glass slides
were incubated with a blocking solution of bovine
serum albumin (BSA)/PBS, washed with PBS, and incu-
bated with normal goat serum (Sigma, St. Louis, USA).
The activity of the endogenous peroxidase was blocked
with a peroxidase blocking reagent (Dako Cytomation,
Inc., California, USA). The cells were then incubated
with avidin and biotin blocking solutions (Avidin/biotin
blocking kit, Vector laboratories, Inc., Burlingame, USA)
to block endogenous avidin and biotin. The cells were
incubated with rat anti-mouse TNFa, IFNg or IL-10
(diluted in ICC cytokine buffer, PharMingen, B-D Bios-
ciences, Canada), washed with PBS, and incubated with
goat anti-rat polyclonal antibody conjugated with perox-
idase (PharMingen, B-D Biosciences, Canada). Vectas-
tain Elite ABC solution (Vector Labs, Burlingame, USA)
was added to cells and incubated with a DAB kit (Vec-
tor Laboratories, Inc., Burlingame, USA). The results
were obtained from two individual blind counts per
each sample (by two different investigators) and were
expressed as number of positive cells counted per 2 ×
104 cells at 1 000X magnification.
Determination of cytokine producing cells in the lamina
propria of the small intestine
The small intestines were removed after 7 days of feed-
ing (Lc and C groups), and 7 and 10 days post Salmo-
nella challenge for all experimental groups, and
processed following the technique described by Sainte-
Marie for paraffin embedding [41]. Tissue sections (4
μm) from each mouse were used to analyze cytokine
producing cells by an indirect immunofluorescence
assay following the technique described previously [11].
The sections were incubated with a blocking solution of
BSA/PBS, washed with PBS, and incubated with normal
goat serum (Sigma, St. Louis, USA) to prevent non-spe-
cific staining. Rabbit anti-mouse TNFa, IFNg, IL-10, and
IL-6 (Peprotech, Inc. Rocky Hill, NJ, USA) polyclonal
antibodies (diluted in saponin-PBS) were applied to the
tissue sections for 105 min at room temperature (RT,
21°C). The sections were then treated 1 h with diluted
goat anti-rabbit antibody conjugated with fluorescein
isothiocyanate (FITC, Jackson Immuno Research, Labs.
Inc. West Grove USA). The results were expressed as
the number of fluorescent cells in 10 fields of vision as
seen with 1 000X magnification using a fluorescent light
microscope. The number of fluorescent cells was
counted for two different investigators (by blind counts)
three times to cover different portions of each sample.
Determination of TNFa, IFNg, IL-10 and IL-6 released in
the small intestine fluid
Intestinal fluid from the small intestines of all the
groups under study were collected with 1 ml of NaCl
0.85% at the same time points that the samples from
intestinal tissues. The fluids were immediately centri-
fuged at 4 000g during 15 min at 4°C. The supernatants
were recovered and stored at -20°C until cytokines
determination by ELISA using the methodology pre-
viously described for cell culture supernatants. The
results were expressed as concentration of each cytokine
in the intestinal fluid (pg/ml).
Immunofluorescence assays for determination of TLR2,
TLR4, TLR5 and TLR9 positive cells on small intestine
tissues
TLR2, TLR4, TLR5 and TLR9 positive cells were
counted in the samples taken at the same time points
used to determine the cytokine producing cells. Posi-
tive cells for each analyzed TLR were counted in the
small intestine tissue (including lamina propria and
epithelium or intraepithelial cells) for all the groups
assayed. After deparaffinization and rehydration, paraf-
fin sections were incubated with solution of 1% BSA
for 30 min at room temperature and washed three
times in PBS. Rat anti-mouse monoclonal TLR2 or
TLR4 (eBioscience, USA) diluted 1:300, rabbit anti-
mouse polyclonal TLR5 (Santa Cruz Biotechnology,
INC) diluted 1:250 or TLR9 (eBioscience, USA) in a
concentration of 0.5 μg/ml antibodies, were applied to
the tissue sections for 105 min at room temperature.
The slides were washed twice with PBS and incubated
for 60 min with a dilution of FITC conjugated goat
anti-rat (1:50) or goat anti-rabbit (1:100) antibody
(Jackson Immuno Research Labs Inc.). The results
were expressed as the number of fluorescent cells in
ten fields of vision at 1 000X of magnification and they
were obtained from two individual blind counts per
each sample (by two different investigators).
Statistical analysis
Each trial, test and control groups contained 10 animals.
Three mice of each group were sacrificed for each sam-
ple taken. The experiments were repeated three times
and all results (from the three trials) were analyzed
together (N = 9). Statistical analyses were performed
using MINITAB 14 software. A factorial experimental
design (replicates - dietary regimen - time point) was
used. Comparisons were accomplished by an ANOVA
general linear model followed by a Tukey’s post hoc test
and p < 0.01 was considered significant. No significant
differences between the three independent replicates
were observed.
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